Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,892,717
  • Shares Outstanding, K 165,770
  • Annual Sales, $ 2,171 M
  • Annual Income, $ 186,000 K
  • 36-Month Beta 0.36
  • Price/Sales 3.14
  • Price/Cash Flow 18.95
  • Price/Book 3.57

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.66 +10.30%
on 05/30/17
42.15 -1.45%
on 06/21/17
+4.26 (+11.43%)
since 05/26/17
3-Month
37.03 +12.18%
on 05/26/17
42.72 -2.76%
on 05/16/17
+1.86 (+4.69%)
since 03/24/17
52-Week
37.03 +12.18%
on 05/26/17
54.73 -24.10%
on 07/11/16
-5.70 (-12.07%)
since 06/24/16

Most Recent Stories

More News
Dr. Reddy's Laboratories Announces the Launch of Bivalirudin for Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version...

RDY : 41.53 (-0.12%)
Dr. Reddy's Laboratories Limited to Present at the Jefferies 2017 Global Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th,...

RDY : 41.53 (-0.12%)
Elite Pharmaceuticals Acquires Trimipramine ANDA

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application ("ANDA") for Trimipramine Maleate...

ELTP : 0.1870 (-3.11%)
RDY : 41.53 (-0.12%)
Dr. Reddy's Laboratories Announces USFDA Approval for the Launch of Doxorubicin Hydrochloride Liposome Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin...

RDY : 41.53 (-0.12%)
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4

Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

AGLE : 3.67 (+2.51%)
GALE : 0.59 (+3.51%)
VVUS : 1.21 (-0.82%)
RDY : 41.53 (-0.12%)
BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

ENDP : 11.88 (+0.34%)
RDY : 41.53 (-0.12%)
BMRN : 93.78 (-1.28%)
SNY : 49.63 (+0.61%)
Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed...

AGIO : 54.35 (-8.16%)
RDY : 41.53 (-0.12%)
Dr. Reddy's Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version...

RDY : 41.53 (-0.12%)
New Strong Sell Stocks for April 20th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

DDS : 54.85 (-0.27%)
F : 11.14 (+0.91%)
RDY : 41.53 (-0.12%)
VTTI : 19.60 (+0.26%)
TXRH : 50.15 (+0.60%)
Mylan Down on FDA Warning Letter to Manufacturing Facility

Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India

MYL : 39.03 (+0.08%)
RDY : 41.53 (-0.12%)
AMGN : 174.08 (+0.92%)
GSK : 44.20 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Support & Resistance

2nd Resistance Point 41.85
1st Resistance Point 41.71
Last Price 41.53
1st Support Level 41.34
2nd Support Level 41.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.